MarketBeat reported on stock consensus ratings, while Decoy Therapeutics announced a partnership with Fox Chase Cancer Center.
1 report, 1 independent
Updated Jun 28
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
MarketBeat reported on stock consensus ratings, while Decoy Therapeutics announced a partnership with Fox Chase Cancer Center.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
MarketBeat
American personal finance blog
-
Fox Chase Cancer Center
research facility and hospital, United States
Nothing else this week.
Related events
- MarketBeat reported consensus rating for Hikma Pharmaceuticals, while Jefferies increased its target price and gave a buy rating. Berenberg Bank reaffirmed its buy rating, and Citigroup restated a buy rating.
- MarketBeat provided stock average ratings while Leerink Partners upgraded and Barclays raised its price objective for Summit Therapeutics.
- MarketBeat reported the consensus rating for Coherus Oncology, Inc.
- MarketBeat provided average rating data for the stock, and Citigroup began coverage on Whitehawk Therapeutics shares.
- MarketBeat provides consensus rating data for GRI Bio, Inc., a company listed on Nasdaq that focuses on modulating NKT cells.